10:44 AM EST - Satellos Bioscience Inc. : Announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses thereof.” The patent includes composition of matter claims covering forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors and related compounds within the company's muscle regeneration platform. Satellos Bioscience Inc.
shares T.MSCL are trading up $0.46 at $12.47.
